drugset / Trial / NCT02216630

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

NCT02216630 ↗

Phase 1/2 Completed 26 enrolled Kimera Society Inc
NaSingle-groupOpen-labelTreatment

Summary

This will be an open-label, non-randomized multi-center study designed to assess the safety and efficacy of Adipose-derived Stem Cell (ASC) IV implantation. The therapy is composed of cells isolated from a patient's own adipose tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.

Timeline

Start
2014-08
Primary completion
2017-07
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Adipose Derived Stem Cell (ADSC) Therapy Cell therapy — Intravenous